Top Markets
#1 Black Phoenix Black Phoenix +355.71%
#2 Glidr Glidr +84.34%
#3 Akedo Akedo +57.01%
#4 Gold Park Gold Park +55.15%
#5 Acurast Acurast +28.90%
#6 BasedHype BasedHype +28.38%
#7 Cryptopia Cryptopia +22.67%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.42%
#9 Avantis Avantis +16.65%
#10 HOME HOME +15.01%
Coin of the day
Black Phoenix Black Phoenix
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Vincerx Pharma, Inc. Vincerx Pharma, Inc.

Vincerx Pharma, Inc.

VINC
Clasificación en acciones #40876
Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical... Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering and advancing innovative treatments for cancer, specifically addressing areas of high medical need within the U.S. Its primary therapeutic asset is VIP152, an inhibitor targeting cyclin-dependent kinase-9 (CDK9), designed for individuals battling advanced forms of cancer. Beyond this lead candidate, the company's pipeline features several preclinical-stage projects: VIP217, an orally administered PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate aimed at solid tumor treatment; and VIP943 and VIP924, both geared towards treating blood cancers. Established in 2019, Vincerx Pharma is based in Palo Alto, California.
Precio por acción
$0.0127
Última sincronización: 2026-08-12
Capitalización bursátil
$66.48K
Cambio (1 día)
-2.31%
Cambio (1 año)
-67.44%
País
US
Comercio Vincerx Pharma, Inc. (VINC)

Categoría

Healthcare
Ganancias de Vincerx Pharma, Inc. (VINC)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Vincerx Pharma, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Vincerx Pharma, Inc. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE